In this week’s Pharma Pulse, Lilly brings Zepbound and Foundayo to Hims & Hers, Swisslog Healthcare expands its Tenutō cold storage line, and FDA adds a NAION warning across the GLP-1 class.
|Podcasts|May 13, 2022
Prioritizing American Manufacturing
Author(s)Nicholas Saraceno, Senior Editor, Julian Upton
Biopharma firm strives to deliver savings to the US healthcare system
Advertisement
David Sanders, vice president of government affairs & policy at biosimilars company Coherus BioSciences, speaks on the firm’s goal of expanding patient access to cost-effective medication, and his role with Securing America’s Medicines and Supply, a coalition of companies aiming to strengthen the security of the US medical supply chain.
The latest episode of The Pharmaceutical Commerce Podcast is available directly on SoundCloud.
Advertisement
Related to this article
In this week’s Pharma Pulse, CVS Health plans to separate into two public companies, Bayer weighs what MFN pricing could mean for its launch strategies and an ACTO survey finds most life sciences leaders see no clear industry standard for responsible AI.
In this week’s Pharma Pulse, GoodRx expands an employer offering built on manufacturer pricing for GLP-1 obesity drugs, a federal judge declines to block Lilly’s comparative Zepbound ads, and the PBM industry’s trade group turns the vertical integration debate toward drug wholesalers.
In this week's Pharma Pulse, Cencora agrees to acquire American Oncology Network, five major employers back electronic prior authorization for self-funded health plans and FDA finalizes its guidance on prescription drug apps and software.
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
CVS Health’s Breakup: A Turning Point for Pharma Supply Chains or a Redistribution of Market Power?
2
Pharma Pulse: Lilly and Hims & Hers Team Up, Swisslog Expands Tenutō Cold Storage
3
Why the Next Wave of Drug Launches Will Be Won on Market Access
4
Executive Conversations: Why Specialty Drug Networks Should Start Small
5